Clinical trials: Hemostatic Disorder
Multiple Myeloma
Monoclonal Antibody-Based Sequential Therapy for Deep Remission in Multiple Myeloma
Multiple myeloma (MM), a plasma cell disorder, is the second most common hematologic malignancy in the U.S. No standard curative therapy has yet been found.
- Trial name
- MASTER (NCT03224507)
- Testing
- KRdD followed by auto-HCT, KRdD only
- Where
- 4 sites in United States
- Volunteers
- 123 people
- Sponsor
- University of Alabama at Birmingham
Purpura, Thrombocytopaenic, Idiopathic
A Longitudinal 2-year Bone Marrow Study of Eltrombopag in Previously Treated Adults, With Chronic Immune (Idiopathic) Thrombocytopenic Purpura (ITP)
A open-label, multi-center 2-year safety study to ascertain the baseline levels of bone marrow fibers in previously treated adults with chronic immune (idiopathic) thrombocytopenic purpura (ITP) and to evaluate the long-term…
- Trial name
- NCT01098487
- Testing
- Eltrombopag olamine
- Where
- 34 sites in United States, Czechia and 9 more
- Volunteers
- 167 people
- Sponsor
- GlaxoSmithKline
Multiple Myeloma
Health Through Activity: A Pilot Study of a Rehabilitation Intervention for People Living With Multiple Myeloma
The purpose of this study is to explore whether a structured program can help reduce the challenges of decreased physical functioning and quality of life for participants with multiple myeloma by providing a customized exercise…
- Trial name
- NCT05700747
- Testing
- Health Through Activity
- Where
- United States
- Volunteers
- 5 people
- Sponsor
- MGH Institute of Health Professions
Haemostasis, Haemophilia A
A Trial Evaluating Efficacy and Safety of Prophylactic Administration of Concizumab in Patients With Severe Haemophilia A Without Inhibitors
This trial is conducted in Asia, Europe and the United States of America (USA). The aim of the trial is to assess the efficacy of concizumab administered s.c.
- Trial name
- explorer™5 (NCT03196297)
- Testing
- Concizumab, Turoctocog alfa
- Where
- 31 sites in United States, France and 9 more
- Volunteers
- 36 people
- Sponsor
- Novo Nordisk A/S
Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma
Iodine I 131 Tositumomab, Etoposide and Cyclophosphamide Followed by Autologous Stem Cell Transplant in Treating Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
This phase II trial is studying how well giving iodine I 131 tositumomab together with etoposide and cyclophosphamide followed by autologous stem cell transplant works in treating patients with relapsed or refractory…
- Conditions
- Anaplastic Large Cell Lymphoma, Cutaneous B-cell Non-Hodgkin Lymphoma, Extranodal Marginal Zone B-cell Lymphoma of Mucosa-associated Lymphoid Tissue, Nodal Marginal Zone B-cell Lymphoma
- Trial name
- NCT00073918
- Testing
- cyclophosphamide, etoposide, iodine I 131 tositumomab
- Where
- United States
- Volunteers
- 111 people
- Sponsor
- Fred Hutchinson Cancer Center
Multiple Myeloma, Kahler Disease
MLN9708 (Ixazomib) in Combination With Panobinostat and Dexamethasone in Multiple Myeloma
This study will look at the safety and tolerability of the new drug MLN9708 in combination with the existing drugs panobinostat and dexamethasone among patients with relapsed or refractory multiple myeloma.
- Conditions
- Multiple Myeloma, Kahler Disease, Plasma-Cell Myeloma, Myelomatosis
- Trial name
- NCT02057640
- Testing
- Panobinostat, Dexamethasone, MLN9708
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- Jason Valent
Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue
Agatolimod Sodium, Rituximab, and Yttrium Y 90 Ibritumomab Tiuxetan in Treating Patients With Recurrent or Refractory Non-Hodgkin Lymphoma
RATIONALE: Biological therapies, such as agatolimod sodium, may stimulate the immune system in different ways and stop cancer cells from growing.
- Conditions
- Adult Non-Hodgkin Lymphoma, Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue, Nodal Marginal Zone Lymphoma, Recurrent Adult Diffuse Large Cell Lymphoma
- Trial name
- NCT00438880
- Testing
- Agatolimod Sodium, Indium In-111 Ibritumomab Tiuxetan, Laboratory Biomarker Analysis
- Where
- 2 sites in United States
- Volunteers
- 38 people
- Sponsor
- Mayo Clinic
Essential Thrombocythemia (ET)
Long-term Safety of SPD422 in Japanese Adults With Essential Thrombocythaemia
The purpose of this study is to provide SPD422 to subjects who completed Study SPD422 308 and, in the opinion of the Investigator, will continue to benefit from treatment.
- Trial name
- NCT01467661
- Testing
- SPD422 (anagrelide hydrochloride)
- Where
- 16 sites in Japan
- Volunteers
- 41 people
- Sponsor
- Shire
Refractory Multiple Myeloma
Bortezomib, Liposomal Doxorubicin Hydrochloride, Dexamethasone, and Cyclophosphamide in Treating Patients With Multiple Myeloma That Relapsed After Autologous Stem Cell Transplant
This phase II trial is studying how well giving bortezomib together with liposomal doxorubicin hydrochloride, dexamethasone, and cyclophosphamide works in treating patients with multiple myeloma that relapsed after autologous…
- Trial name
- NCT01078441
- Testing
- liposomal doxorubicin, bortezomib, dexamethasone
- Where
- 130 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Multiple Myeloma
Autologous Stem Cell Transplant With Pomalidomide (CC-4047®) Maintenance Versus Continuous Clarithromycin/ Pomalidomide / Dexamethasone Salvage Therapy in Relapsed or Refractory Multiple Myeloma
The purpose of this study is to see whether pomalidomide (also known as Pomalyst) reduces the number of myeloma cells in the bones, and to see what is the best way to use pomalidomide in patients with myeloma.
- Trial name
- NCT01745588
- Testing
- Pomalidomide, stem cell, Dexamethasone
- Where
- 10 sites in United States
- Volunteers
- 23 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Hemophilia A
Trial to Evaluate the Effect of Secondary Prophylaxis With rFVIII Therapy in Severe Hemophilia A Adult and/or Adolescent Subjects Compared to That of Episodic Treatment
To evaluate the effect of secondary prophylaxis as compared to episodic treatment on bleeding frequency (number of bleeds per year) and on joint damage.
- Trial name
- SPINART (NCT00623480)
- Testing
- Recombinant Factor VIII (Kogenate FS, BAY14-2222)
- Where
- 38 sites in United States, Argentina and 2 more
- Volunteers
- 84 people
- Sponsor
- Bayer
Non-Hodgkin's Lymphoma, Acute Leukemia in Remission
Calcineurin Inhibitor-Free GVHD Prevention Regimen After Related Haplo PBSCT
The purpose of this study is to find out if a combination of drugs (these are called: cyclophosphamide, sirolimus, and mycophenolate mofetil) will protect participants better against graft vs.
- Conditions
- Non-Hodgkin's Lymphoma, Acute Leukemia in Remission, Chronic Myeloid Leukemia, Primary Myelofibrosis
- Trial name
- NCT03018223
- Testing
- Fludarabine, Busulfan, Cyclophosphamide
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- H. Lee Moffitt Cancer Center and Research Institute
Primary Immune Deficiency Disorders, Common Variable Immunodeficiency
A Study to Find Out How Safe and Effective Gammaplex® is in Young People With Primary Immunodeficiency
The main objective is to determine the efficacy of Gammaplex by measuring the number of serious acute bacterial infections during treatment with Gammaplex over a 12 month period.
- Conditions
- Primary Immune Deficiency Disorders, Common Variable Immunodeficiency, X-linked Agammaglobulinemia, Hyper-IgM Syndrome
- Trial name
- NCT01289847
- Testing
- Gammaplex
- Where
- 10 sites in United States, Chile and 1 more
- Volunteers
- 25 people
- Sponsor
- Bio Products Laboratory
Reversal of Anticoagulant Treatment
Study of Octaplex (Human Prothrombin Complex Concentrate) and Fresh Frozen Plasma in Patients Under Vitamin K Therapy Antagonist Needing Urgent Surgery or Invasive Procedures
The purpose of this study is to determine whether Octaplex (human prothrombin complex concentrate) can reverse the effects of anticoagulants when compared to the standard treatment of fresh frozen plasma (FFP).
- Trial name
- NCT00618098
- Testing
- Octaplex (human prothrombin complex concentrate), Fresh frozen plasma
- Where
- United States
- Volunteers
- 200 people
- Sponsor
- Octapharma
Cancer Prevention, Weight Loss
PROFAST Intervention in Precursor Multiple Myeloma
This is a 4-month randomized trial of a prolonged nightly fasting intervention (PROFAST) in 40 overweight and obese individuals with monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM)…
- Conditions
- Cancer Prevention, Weight Loss, Smoldering Waldenstrom Macroglobulinemia(WM), MGUS
- Trial name
- PROFAST (NCT05565638)
- Testing
- Prolonged Fasting Intervention, EDUCATION CONTROL
- Where
- United States
- Volunteers
- 23 people
- Sponsor
- Dana-Farber Cancer Institute
Waldenstrom's Macroglobulinemia
Ibrutinib (PCI-32765) in Waldenstrom's Macroglobulinemia
This research study is a Phase II clinical trial. Phase II clinical trials test the effectiveness of an investigational drug, PCI-32765, to learn whether PCI-32765 works in treating a specific cancer.
- Trial name
- NCT01614821
- Testing
- PCI-32765
- Where
- 4 sites in United States
- Volunteers
- 63 people
- Sponsor
- Dana-Farber Cancer Institute
Multiple Myeloma
Phase 2 Study of Carfilzomib in Relapsed and Refractory Multiple Myeloma
To evaluate the overall response rate and safety and tolerability of carfilzomib in subjects with relapsed and refractory multiple myeloma.
- Trial name
- NCT00511238
- Testing
- carfilzomib
- Where
- 34 sites in United States, Canada
- Volunteers
- 312 people
- Sponsor
- Amgen
Leukemia, Myeloid, Acute, Myelodysplastic Syndromes
Plerixafor and Sargramostim (GM-CSF) for Mobilization of Allogeneic Sibling Donors
This study will gather information about the combination the drugs plerixafor with sargramostim in donors of blood-forming cells (stem cells). These stem cells will be collected from the donor and transplanted into their sibling.
- Conditions
- Leukemia, Myeloid, Acute, Myelodysplastic Syndromes, Lymphoma, Non-Hodgkin, Hodgkin Disease
- Trial name
- NCT01158118
- Testing
- Sargramostim, Plerixafor
- Where
- United States
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Multiple Myeloma
Study of Ibrutinib in Combination With Pomalidomide and Dexamethasone in Subjects With Relapsed/Refractory Multiple Myeloma
Phase 1 is an open-label, dose finding, multicenter study of ibrutinib in combination with pomalidomide and dexamethasone in subjects with relapsed/refractory multiple myeloma.
- Trial name
- NCT02548962
- Testing
- Ibrutinib, Pomalidomide, Dexamethasone
- Where
- 16 sites in United States, Australia and 4 more
- Volunteers
- 11 people
- Sponsor
- Pharmacyclics LLC.
Multiple Myeloma
Dasatinib in Combination With Revlimid (and Dexamethasone)
The purpose of this study was to determine the safety and tolerability of dasatinib when given in combination with lenalidomide and a low dose dexamethasone for the treatment of relapsed or refractory multiple myeloma.
- Trial name
- NCT00560391
- Testing
- Dasatinib, 70 mg + Lenalidomide, 15 mg + Dexamethasone, 40 mg, Dasatinib, 70 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg, Dasatinib, 100 mg + Lenalidomide, 20 mg + Dexamethasone, 40 mg
- Where
- 4 sites in United States, Australia and 1 more
- Volunteers
- 35 people
- Sponsor
- Bristol-Myers Squibb
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.